Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 210

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians

Open access
Arends, Pauline, Sonneveld, Milan J, Zoutendijk, Roeland, Carey, Ivana, Brown, Ashley, Fasano, Massimo, Mutimer, David, Deterding, Katja, Reijnders, Jurriën G P, Oo, Ye, Petersen, Jörg, van Bömmel, Florian, de Knegt, Robert J, Santantonio, Teresa, Berg, Thomas, Welzel, Tania M, Wedemeyer, Heiner, Buti, Maria, Pradat, Pierre, Zoulim, Fabien, Hansen, Bettina, Janssen, Harry L A · 2015 · Gut

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) risk-scores may predict HCC in Asian entecavir (ETV)-treated patients. We aimed to study risk factors and performance of risk scores during ETV treatment in an ethnically diverse Western population. METHODS: We studied all HBV monoinfected patients treated with ETV from 11 European referral centres within the VIRGIL Network. RESULTS: A total of 744 patients were included; 42% Caucasian, 29% Asian, 19% other, 10% unknown. At baseline, 164 patients (22%) had cirrhosis. During a median follow-up of 167 (IQR 82-212) weeks, 14 patients developed HCC of whom nine (64%) had cirrhosis at baseline. The 5-year cumulative incidence rate of HCC was 2.1% for non-cirrhotic and 10.9% for cirrhotic patients (p<0.001). HCC incidence was higher in older patients (p<0.001) and patients with lower baseline platelet counts (p=0.02). Twelve patients who developed HCC achieved virologic response (HBV DNA <80 IU/mL) before HCC. At baseline, higher CU-HCC and GAG-HCC, but not REACH-B scores were associated with development of HCC. Discriminatory performance of HCC risk scores was low, with sensitivity ranging from 18% to 73%, and c-statistics from 0.71 to 0.85. Performance was further reduced in Caucasians with c-statistics from 0.54 to 0.74. Predicted risk of HCC based on risk-scores declined during ETV therapy (all p<0.001), but predictive performances after 1 year were comparable to those at baseline. CONCLUSIONS: Cumulative incidence of HCC is low in patients treated with ETV, but ETV does not eliminate the risk of HCC. Discriminatory performance of HCC risk scores was limited, particularly in Caucasians, at baseline and during therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2014-307023

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 210

Metadata

Authors
Arends, P., Sonneveld, M. J., Zoutendijk, R., Carey, I., Brown, A., Fasano, M., Mutimer, D., Deterding, K., Reijnders, J. G. P., Oo, Y., Petersen, J., van Bömmel, F., de Knegt, R. J., Santantonio, T., Berg, T., Welzel, T. M., Wedemeyer, H., Buti, M., Pradat, P., Zoulim, F., Hansen, B., & Janssen, H. L. A.
Venue
Gut
Publisher
BMJ
Published
2014-07-10
Volume
64
Issue
8
Pages
1289-1295
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2105393604
Cited by
210
References
1
FWCI
17.75
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. https://app.cochat.ai/papers/10.1136/gutjnl-2014-307023
The paper
Arends, P., Sonneveld, M. J., Zoutendijk, R., Carey, I., Brown, A., Fasano, M., Mutimer, D., Deterding, K., Reijnders, J. G. P., Oo, Y., Petersen, J., van Bömmel, F., de Knegt, R. J., Santantonio, T., Berg, T., Welzel, T. M., Wedemeyer, H., Buti, M., Pradat, P., . . . Janssen, H. L. A. (2015). Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians. Gut. https://doi.org/10.1136/gutjnl-2014-307023

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.